Contact Us
Soft Tissue Sarcoma Global Market Report 2025
Global Soft Tissue Sarcoma Market Report 2025
Item added to cart!

Published : December 2025

Pages : 200

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00 $3367.00

Purchase This Report Download Sample PDF
Purchase This Report

Soft Tissue Sarcoma Global Market Report 2025

By Treatment (Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments), By Route of Administration (Oral, Parenteral, Other Route of Administrations), By End-Users (Hospitals, Homecare, Specialty Centers, Other End-Users) – Impact of Tariff and Trade War on Market Size, Growth, Trends, and Forecast 2025–2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Soft Tissue Sarcoma Market Overview

• Soft Tissue Sarcoma market size has reached to $3.15 billion in 2024

• Expected to grow to $4.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%

• Growth Driver: Surge In Cancer Incidence Driving Soft Tissue Sarcoma Market Growth

• Market Trend: Product Innovation Driving Advancements In Soft Tissue Sarcoma Market

North America was the largest region in 2024 and Asia-Pacific is the fastest growing region.

What Is Covered Under Soft Tissue Sarcoma Market?

Soft tissue sarcoma refers to a disease where cancer cells form in the soft tissues of the body which can be diagnosed through biopsy techniques. It is commonly caused in tissues including blood arteries, muscle, neurons, and fat.

The main treatment types of soft tissue sarcoma are targeted therapy, chemotherapy, anti-angiogenesis drugs, radiation therapy, and others. Targeted therapy refers to treatment that specifically targets the genes, proteins, or tissue environment that supports the growth and survival of cancer and prevents cancer cells from proliferating, dividing, and creating new cells. The various routes of administration include oral, parenteral, and others. These are used by various end-users such as hospitals, homecare, specialty centers, and others.

Soft Tissue Sarcoma Market Size and growth rate 2025 to 2029: Graph

What Is The Soft Tissue Sarcoma Market Size 2025 And Growth Rate?

The soft tissue sarcoma market size has grown strongly in recent years. It will grow from $3.15 billion in 2024 to $3.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to limited treatment options, evolving understanding of sarcoma biology, growth in cancer research funding, rising prevalence of soft tissue sarcoma, and expansion of healthcare infrastructure

What Is The Soft Tissue Sarcoma Market Growth Forecast?

The soft tissue sarcoma market size is expected to see strong growth in the next few years. It will grow to $4.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to development of targeted therapies for soft tissue sarcoma, increasing focus on personalized medicine, expansion of clinical trials for sarcoma treatments, growing awareness and early detection initiatives.Major trends in the forecast period include integration of immunotherapy in soft tissue sarcoma treatment, development of combination therapies, emphasis on patient-centric care models, rise in the use of liquid biopsies, advances in sarcoma genomics.

The forecast of 8.6% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. cancer care by increasing costs for targeted immunotherapy drugs and specialized biopsy tools imported from Japan and Belgium, potentially compromising sarcoma treatment efficacy and raising oncology department expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Customer representative image Book your 30 minutes free consultation with our research experts

What’s The Trade War Impact On Healthcare Services Industry?

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

How Is The Soft Tissue Sarcoma Market Segmented?

1) By Treatment: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments

2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations

3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Subsegments:

1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Immunotherapy Agents

2) By Chemotherapy: Doxorubicin, Ifosfamide, Gemcitabine, Other Chemotherapeutic Agents

3) By Anti-Angiogenesis Drugs: Bevacizumab, Pazopanib, Axitinib, Other Anti-Angiogenesis Agents

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy

5) By Other Treatments: Surgery, Clinical Trials, Supportive Care

What Is Driving The Soft Tissue Sarcoma Market? Surge In Cancer Incidence Driving Soft Tissue Sarcoma Market Growth

The surge in cancer incidence is expected to propel the growth of the soft tissue sarcoma market going forward. Cancer is a broad category of illnesses that can develop in any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. The rise in cancer incidence increases the need for diagnostic procedures, therapeutic regimens, and supportive care choices to meet the unique requirements of patients with several types of cancer or sarcoma, which boosts the market for soft tissue sarcomas For instance, in January 2024, according to the World Health Organization, a Switzerland-based Intergovernmental organization published that by 2050, it is projected that there will be over 35 million new cancer cases, marking a 77% increase from the estimated 20 million cases and 9.7 million deaths recorded in 2022. Therefore, the surge in cancer incidence is driving the growth of the soft tissue sarcoma industry.

What Is Driving The Soft Tissue Sarcoma Market? Increasing Healthcare Expenditure Fuels Growth Of Soft Tissue Sarcoma Market

The increasing healthcare expenditure is expected to propel the growth of the soft tissue sarcoma market. Healthcare refers to the organized provision of medical services, treatments, preventive care, and management of health-related issues for individuals or communities. Higher healthcare expenditures can result in increased funding for medical research, including cancer research. This can lead to advancements in understanding soft tissue sarcoma, discovering new treatment modalities, and improving overall patient outcomes. For instance, in May 2023, according to a report published by the Office for National Statistics, a UK-based government department, between 2022 and 2023, healthcare spending in the UK increased by 5.6% compared with growth of 0.9% in 2022. The UK healthcare expenditure in UK healthcare expenditure was around $317.63 billion (£292 billion) in 2023. Therefore, the increased healthcare expenditure will drive the growth of the soft tissue sarcoma industry.

Who Are The Major Players In The Global Soft Tissue Sarcoma Market?

Major companies operating in the soft tissue sarcoma market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.

What Are The Key Trends Of The Global Soft Tissue Sarcoma Market? Product Innovation Driving Advancements In Soft Tissue Sarcoma Market

Product innovation has emerged as a key trend gaining popularity in the soft tissue sarcoma market. Major companies operating in the soft tissue sarcoma market are concentrating on creating innovative products to strengthen their position in the market. For instance, in November 2023, Mercy, a US-based not-for-profit Catholic healthcare organization, introduced an innovative AI-driven texting program called The Chen Chemotherapy Model to proactively prevent hospitalizations related to chemotherapy. This program utilizes a smart texting platform that sends daily messages to chemotherapy patients seven days a week, excluding weekends and holidays. The texts present a list of symptoms, including diarrhea, pain, fever, fatigue, nausea or vomiting, or no symptoms. Patients can select and rate their symptoms, and based on their responses, the information may be escalated to their healthcare provider. The goal is to identify potential issues early and intervene before symptoms worsen, demonstrating Mercy's commitment to leveraging technology for improved patient care in the field of chemotherapy.

What Are The Key Trends Of The Global Soft Tissue Sarcoma Market? Research Initiatives Shaping The Soft Tissue Sarcoma Market Landscape

Major companies operating in the soft tissue sarcoma market are focusing on research projects such as the Leiomyosarcoma Project (LMS) to sustain their position in the market. Leiomyosarcoma Project (LMS) refers to a project that aims to advance scientific discovery and understanding of leiomyosarcoma, which is a rare and aggressive form of cancer that arises in smooth muscle cells, typically found in the walls of organs such as the uterus, stomach, or intestines. For instance, in September 2022, Count Me In, a US-based non-profit cancer research initiative, launched the Leiomyosarcoma Project (LMS), inviting individuals with the rare cancer leiomyosarcoma to actively participate in research. This initiative aims to accelerate scientific discovery and enhance understanding of leiomyosarcoma by partnering with patients. Count Me In already runs the Osteosarcoma Project (OS), another rare cancer research effort, following a similar patient-partnered model. In these projects, patients are encouraged to share their health data, contributing to a collaborative and data-driven approach to advance research and improve outcomes for individuals with these rare cancers.

Need data on a specific region in this market?

Soft Tissue Sarcoma Market Merger And Acquisition: Ipsen Sa Acquires Epizyme Inc. For Soft Tissue Sarcoma Drug Portfolio

In August 2022, Ipsen SA, a France-based biopharmaceutical company, acquired Epizyme Inc. for an undisclosed amount. Through this acquisition, Ipsen SA accesses the Tazverik (tazemetostat) lead drug developed by Epizyme, a first-in-class, chemotherapy-free EZH2a inhibitor, and acquires EZM0414, a first-in-class, oral SETD2 inhibitor. Epizyme Inc. is a US-based biopharmaceutical company that develops drugs for treating soft tissue sarcoma.

Regional Outlook For The Global Soft Tissue Sarcoma Market

North America was the largest region in the soft tissue sarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Soft Tissue Sarcoma Market?

The soft tissue sarcoma includes revenues earned by entities by immunotherapy, hormone therapy, photodynamic therapy, and stem cell transplant. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Soft Tissue Sarcoma Industry?

The soft tissue sarcoma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the soft tissue sarcoma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Girish Kavali

Soft Tissue Sarcoma Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $3.41 billion
Revenue Forecast In 2034 $4.74 billion
Growth Rate CAGR of 8.6% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Treatment: Targeted Therapy, Chemotherapy, Anti-Angiogenesis Drugs, Radiation Therapy, Other Treatments
2) By Route Of Administration: Oral, Parenteral, Other Route Of Administrations
3) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users Subsegments: 1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), Monoclonal Antibodies, Immunotherapy Agents
2) By Chemotherapy: Doxorubicin, Ifosfamide, Gemcitabine, Other Chemotherapeutic Agents
3) By Anti-Angiogenesis Drugs: Bevacizumab, Pazopanib, Axitinib, Other Anti-Angiogenesis Agents
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy
5) By Other Treatments: Surgery, Clinical Trials, Supportive Care
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Soft Tissue Sarcoma Market Characteristics

3. Soft Tissue Sarcoma Market Trends And Strategies

4. Soft Tissue Sarcoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Soft Tissue Sarcoma Growth Analysis And Strategic Analysis Framework

5.1. Global Soft Tissue Sarcoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Soft Tissue Sarcoma Market Growth Rate Analysis

5.4. Global Soft Tissue Sarcoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Soft Tissue Sarcoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Soft Tissue Sarcoma Total Addressable Market (TAM)

6. Soft Tissue Sarcoma Market Segmentation

6.1. Global Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Targeted Therapy

Chemotherapy

Anti-Angiogenesis Drugs

Radiation Therapy

Other Treatments

6.2. Global Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

Other Route Of Administrations

6.3. Global Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Homecare

Specialty Centers

Other End-Users

6.4. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Tyrosine Kinase Inhibitors (TKIs)

Monoclonal Antibodies

Immunotherapy Agents

6.5. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Doxorubicin

Ifosfamide

Gemcitabine

Other Chemotherapeutic Agents

6.6. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Anti-Angiogenesis Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Bevacizumab

Pazopanib

Axitinib

Other Anti-Angiogenesis Agents

6.7. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

External Beam Radiation Therapy (EBRT)

Brachytherapy

6.8. Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Surgery

Clinical Trials

Supportive Care

7. Soft Tissue Sarcoma Market Regional And Country Analysis

7.1. Global Soft Tissue Sarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Soft Tissue Sarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Soft Tissue Sarcoma Market

8.1. Asia-Pacific Soft Tissue Sarcoma Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Soft Tissue Sarcoma Market

9.1. China Soft Tissue Sarcoma Market Overview

9.2. China Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Soft Tissue Sarcoma Market

10.1. India Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Soft Tissue Sarcoma Market

11.1. Japan Soft Tissue Sarcoma Market Overview

11.2. Japan Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Soft Tissue Sarcoma Market

12.1. Australia Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Soft Tissue Sarcoma Market

13.1. Indonesia Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Soft Tissue Sarcoma Market

14.1. South Korea Soft Tissue Sarcoma Market Overview

14.2. South Korea Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Soft Tissue Sarcoma Market

15.1. Western Europe Soft Tissue Sarcoma Market Overview

15.2. Western Europe Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Soft Tissue Sarcoma Market

16.1. UK Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Soft Tissue Sarcoma Market

17.1. Germany Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Soft Tissue Sarcoma Market

18.1. France Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Soft Tissue Sarcoma Market

19.1. Italy Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Soft Tissue Sarcoma Market

20.1. Spain Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Soft Tissue Sarcoma Market

21.1. Eastern Europe Soft Tissue Sarcoma Market Overview

21.2. Eastern Europe Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Soft Tissue Sarcoma Market

22.1. Russia Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Soft Tissue Sarcoma Market

23.1. North America Soft Tissue Sarcoma Market Overview

23.2. North America Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Soft Tissue Sarcoma Market

24.1. USA Soft Tissue Sarcoma Market Overview

24.2. USA Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Soft Tissue Sarcoma Market

25.1. Canada Soft Tissue Sarcoma Market Overview

25.2. Canada Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Soft Tissue Sarcoma Market

26.1. South America Soft Tissue Sarcoma Market Overview

26.2. South America Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Soft Tissue Sarcoma Market

27.1. Brazil Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Soft Tissue Sarcoma Market

28.1. Middle East Soft Tissue Sarcoma Market Overview

28.2. Middle East Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Soft Tissue Sarcoma Market

29.1. Africa Soft Tissue Sarcoma Market Overview

29.2. Africa Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Soft Tissue Sarcoma Market Competitive Landscape And Company Profiles

30.1. Soft Tissue Sarcoma Market Competitive Landscape

30.2. Soft Tissue Sarcoma Market Company Profiles

30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Soft Tissue Sarcoma Market Other Major And Innovative Companies

31.1. Bayer AG

31.2. Novartis AG

31.3. Sanofi SA

31.4. Bristol Myers Squibb

31.5. AstraZeneca plc

31.6. GlaxoSmithKline plc

31.7. Takeda Pharmaceutical Company Limited

31.8. Eli Lilly and Company

31.9. Merck & Co. Inc.

31.10. Amgen Inc.

31.11. Teva Pharmaceutical Industries Ltd.

31.12. Mylan N.V.

31.13. Astellas Pharma Inc.

31.14. Daiichi Sankyo Company Limited

31.15. Sun Pharmaceutical Industries Ltd.

32. Global Soft Tissue Sarcoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Soft Tissue Sarcoma Market

34. Recent Developments In The Soft Tissue Sarcoma Market

35. Soft Tissue Sarcoma Market High Potential Countries, Segments and Strategies

35.1 Soft Tissue Sarcoma Market In 2029 - Countries Offering Most New Opportunities

35.2 Soft Tissue Sarcoma Market In 2029 - Segments Offering Most New Opportunities

35.3 Soft Tissue Sarcoma Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Anti-Angiogenesis Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Soft Tissue Sarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Soft Tissue Sarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Pfizer Inc. Financial Performance
  • Table 80: Johnson & Johnson Financial Performance
  • Table 81: Roche Holding AG Financial Performance
  • Table 82: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 83: AbbVie Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Anti-Angiogenesis Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Soft Tissue Sarcoma Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Soft Tissue Sarcoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Soft Tissue Sarcoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Soft Tissue Sarcoma Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Soft Tissue Sarcoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Soft Tissue Sarcoma Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Pfizer Inc. Financial Performance
  • Figure 80: Johnson & Johnson Financial Performance
  • Figure 81: Roche Holding AG Financial Performance
  • Figure 82: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 83: AbbVie Inc. Financial Performance

Frequently Asked Questions

Soft tissue sarcoma refers to a disease where cancer cells form in the soft tissues of the body which can be diagnosed through biopsy techniques. It is commonly caused in tissues including blood arteries, muscle, neurons, and fat. For further insights on this market, request a sample here

The market major growth driver - Surge In Cancer Incidence Driving Soft Tissue Sarcoma Market Growth. For further insights on this market, request a sample here

The soft tissue sarcoma market size has grown strongly in recent years. It will grow from $3.15 billion in 2024 to $3.41 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to limited treatment options, evolving understanding of sarcoma biology, growth in cancer research funding, rising prevalence of soft tissue sarcoma, and expansion of healthcare infrastructure. The soft tissue sarcoma market size is expected to see strong growth in the next few years. It will grow to " $4.74 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to development of targeted therapies for soft tissue sarcoma, increasing focus on personalized medicine, expansion of clinical trials for sarcoma treatments, growing awareness and early detection initiatives.Major trends in the forecast period include integration of immunotherapy in soft tissue sarcoma treatment, development of combination therapies, emphasis on patient-centric care models, rise in the use of liquid biopsies, advances in sarcoma genomics. For further insights on this market, request a sample here

The soft tissue sarcomamarket covered in this report is segmented –
1) By Treatment: Targeted Therapy; Chemotherapy; Anti-Angiogenesis Drugs; Radiation Therapy; Other Treatments
2) By Route Of Administration: Oral; Parenteral; Other Route Of Administrations
3) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users Subsegments:
1) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs); Monoclonal Antibodies; Immunotherapy Agents
2) By Chemotherapy: Doxorubicin; Ifosfamide; Gemcitabine; Other Chemotherapeutic Agents
3) By Anti-Angiogenesis Drugs: Bevacizumab; Pazopanib; Axitinib; Other Anti-Angiogenesis Agents
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Brachytherapy
5) By Other Treatments: Surgery; Clinical Trials; Supportive Care For further insights on this market,
request a sample here

North America was the largest region in the soft tissue sarcoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the soft tissue sarcoma market report during the forecast period. The regions covered in the soft tissue sarcoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on this market, request a sample here.

Major companies operating in the soft tissue sarcoma market include Pfizer Inc., Johnson & Johnson, Roche Holding AG, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol Myers Squibb, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Merck & Co. Inc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Ltd., Lupin Ltd., Philogen S.p.A., Taiho Pharmaceutical Co.Ltd., Nanobiotix S.A. . For further insights on this market, request a sample here.

Major trends in this market include Product Innovation Driving Advancements In Soft Tissue Sarcoma Market. For further insights on this market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Back to top WhatsApp icon